Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review

Anti-VEGF (vascular endothelial growth factor) therapy with the monoclonal antibody bevacizumab can cause gastrointestinal (GI) perforations. In recent years it became apparent that GI perforations also occur during treatment with antiangiogenic tyrosine kinase inhibitors (TKIs). It is of clinical i...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Walraven, Maudy, Witteveen, Petronella O., Lolkema, Martijn P. J., van Hillegersberg, R., Voest, Emile E., Verheul, H. M. W.
Format: Artigo
Langue:Inglês
Publié: Springer Netherlands 2010
Sujets:
Original Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3102838/
https://ncbi.nlm.nih.gov/pubmed/21188500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10456-010-9197-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires